Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial

Clicks: 318
ID: 111019
2020
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #8 of 13 articles by views in Haematologica

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
n the EMN01 trial, the addition of an alkylator (melphalan or cyclophosphamide) to lenalidomide-steroid induction therapy was prospectively evaluated in transplant-ineligible patients with multiple myeloma. After induction, patients were randomly assigned to maintenance treatment with lenalidomide a …
Reference Key
s2020haematologicalenalidomide-based Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bringhen S;D'Agostino M;Paris L;Ballanti S;Pescosta N;Spada S;Pezzatti S;Grasso M;Rota-Scalabrini D;De Rosa L;Pavone V;Gazzera G;Aquino S;Poggiu M;Santoro A;Gentile M;Baldini L;Petrucci MT;Tosi P;Marasca R;Cellini C;Palumbo A;Falco P;Hájek R;Boccadoro M;Larocca A;;
Journal Haematologica
Year 2020
DOI
DOI not found
URL
https://www.pubmed.gov/31582542/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE pubmed abstract nih national institutes of health national library of medicine pmid:31582542 pmc7327625 doi:10.3324/haematol.2019.226407 sara bringhen mattia d'agostino alessandra larocca

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.